Veraxa Biotech AG - Post de-SPAC SEC filings VRXAW

Veraxa Biotech AG - Post de-SPAC has 56 filings in SEC EDGAR's recent list, going back to Jul 31, 2025. Its latest annual report, Form 20-F, was filed on Jun 16, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 15, 2026. The company's fiscal year ends on December 31.

Veraxa Biotech AG - Post de-SPAC SEC filings
Form Description Filed Period
EFFECT Filing Aug 6, 2026 —
EFFECT Filing Aug 6, 2026 —
CERT Filing Jun 10, 2026 —
8-A12B/A Filing Jun 10, 2026 —
8-A12B Filing Jun 9, 2026 —
EFFECT Filing Feb 17, 2026 —
CORRESP Letter to the SEC Feb 13, 2026 —
CORRESP Letter to the SEC Feb 12, 2026 —
UPLOAD Letter from the SEC Feb 11, 2026 —
CORRESP Letter to the SEC Nov 28, 2025 —
UPLOAD Letter from the SEC Nov 20, 2025 —
425 Filing Sep 30, 2025 —
CORRESP Letter to the SEC Sep 29, 2025 —
UPLOAD Letter from the SEC Aug 27, 2025 —

Showing 14 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
VRXA (Nasdaq), VRXAW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Switzerland
Headquarters
Zurich
SEC filer status
, Emerging growth company
SEC CIK
2079109
Former names
Veraxa Biotech Holding AG (until Aug 13, 2026)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.